Seeking Alpha

Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...
Business Wire

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
ascopubs.org

POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).

Harnessing transcriptome signatures and CD103+CD8+ immune infiltration for prognosis and treatment outcomes in anal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Seeking Alpha

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...
ascopubs.org

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study.

Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
Nasdaq

Clearside Biomedical Presents Subgroup Analyses from ODYSSEY Phase 2b Clinical Trial for CLS-AX at Angiogenesis 2025 Meeting

Clearside Biomedical, Inc. has announced the presentation of two subgroup analyses from its ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. The trial ...
The American Journal of Managed Care

Key Takeaways From CEPHEUS: Subgroup Analysis

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...
Business Wire

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...